Kristen Fortney, BioAge Labs CEO
Next-gen obesity biotech BioAge Labs to raise $198M in IPO
A California biotech that began as an anti-aging company, then licensed an Amgen heart failure drug for $1 million upfront and repurposed it as a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
